Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients. The salivary gland data come from a phase 1a trial that tested the PDC AVA6000 in patients with various FAP-positive solid tumors. AVA6000 consists of a chemotherapy drug, doxorubicin, bound to a linker that is cleaved by FAP. Source: Fierce Biotech 16/1/2025